Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Infarct volume refers to the quantitative measurement of the amount of brain tissue that has undergone irreversible injury due to loss of blood supply following an acute ischemic event such as stroke. It is typically measured using neuroimaging techniques like MRI diffusion-weighted imaging or CT scans. Infarct volume serves as an objective surrogate marker for clinical outcome in both research and clinical trials on acute ischemic stroke therapies[1][2][3]. Larger final infarct volumes are strongly correlated with more severe neurological deficits and poorer functional recovery. Measurement methods include manual tracing on imaging slices, semiautomated software algorithms, or estimation formulas such as ABC/2[3][4]. The timing of measurement is important because early measurements may be confounded by edema; final assessment is usually performed at least 30 days post-stroke when the lesion stabilizes[1][2]. While crucial for evaluating treatment efficacy and prognosis in cerebrovascular disease studies, "infarct volume" itself does not represent a molecular entity or therapeutic target but rather an anatomical/radiological outcome variable.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Infarct volume (None).